Overexpression of NDRG2 promotes the therapeutic effect of pazopanib on ovarian cancer

Ying Cui1, Guihua Shen1, Linlin Ma1

  • 1Department of Gynecology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China.

Insights

N-myc downstream-regulated gene 2 (NDRG2) overexpression enhances pazopanib

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Ovarian cancer is frequently diagnosed at advanced stages in the US.
  • Pazopanib, an FDA-approved tyrosine kinase inhibitor, is used in cancer treatment.
  • N-myc downstream-regulated gene 2 (NDRG2) acts as a tumor suppressor, inhibiting cancer cell proliferation, invasion, and migration.

Purpose of the Study:

  • To investigate the role of NDRG2 in ovarian cancer progression.
  • To determine if NDRG2 can enhance the efficacy of pazopanib.
  • To explore the underlying molecular mechanisms involving the ASK1/JNK1 signaling pathway.

Main Methods:

  • NDRG2 was overexpressed or inhibited in the SKOV-3 ovarian cancer cell line.
  • Apoptosis was assessed via flow cytometry.
  • Metastasis and angiogenesis factors were quantified using qPCR and ELISA, respectively.
  • Protein expression, including apoptosis-related proteins and the ASK1/JNK1 pathway, was analyzed by western blotting.

Main Results:

  • Overexpression of NDRG2 potentiated pazopanib's inhibitory effects on metastasis and angiogenesis in SKOV-3 cells.
  • NDRG2 overexpression significantly enhanced cancer cell apoptosis.
  • These effects were mediated by the activation of the ASK1/JNK1 signaling pathway.

Conclusions:

  • NDRG2 plays a crucial role in suppressing ovarian cancer progression.
  • NDRG2 may serve as a valuable therapeutic target for ovarian cancer treatment.
  • The ASK1/JNK1 pathway is implicated in NDRG2-mediated anti-cancer effects.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K